Making Tomorrow’s
Cancer Treatment Better
We are Isofol
Isofol is a publicly listed biotech company developing the drug candidate arfolitixorin to enhance the efficacy of standard treatment for patients with severe forms of cancer.
Our goal is s to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life.
Isofol’s share is listed on Nasdaq Stockholm.
Latest press releases
New visual identity
Most welcome to our new website and our new visual identity! The identity has been created partly to give us a more powerful and unified expression in all communication, but also to give us a more human approach. Our ambition is to become a more distinctive brand that conveys the essence of our business, and this identity is an important tool to achieve that.
2025-11-14
Investor Meeting
On November 13 Isofol invited to an investor meeting to provide an update on the company’s ongoing clinical study with the drug candidate arfolitixorin.
2025-10-08
CEO interview
Isofol’s CEO, Petter Segelman Lindqvist, was interviewed by Dagens Industri Investor Relations for an update on the company.
For investors
Upcoming Events
- November 20, 2025 - November 20, 2025
Redeye Investor Forum, Gothenburg
Isofol attending during this day with a short presentation followed by a live Q&A session with Redeye’s analysts. - December 03, 2025 - December 03, 2025
Redeye Life Science Day 2025, Stockholm
Isofol attending during this day with a short presentation followed by a live Q&A session with Redeye’s analysts. - February 18, 2026 - February 18, 2026
Year-end report 2025
Latest reports and presentations
